icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
eNrNWF1v2jAUfedXRHlPQrK20ClQbazdkFqNUdCmvVQmuRRnxk79QWG/fk5CO6gStTW11DdiO+de+x6fe0h8tl4SZwVcYEZ7bui3XQdowlJMb3vudHLhdd2zfivO0ArtLNPr/ChynYQgIXpuMevPAFHh/7q6/AL6feBuv+XEbJZBIvfWKYmJ/w2JxRXKizVOvGI4dZYgFyztubmS5agTC8l1Fv17xv+IHCUQB9uR3dns5mh3PA4KsBegKgH8EtHbWlCgRpiJ4hyoHCAJt4xvGvL9YISNxRgEUzyBEZKLEWcrnEJaG2KOiACjIPP79Br4ioAsgtSCB1myFEbgKEPrMdwN65P+pGcHci29thd2wk63c9xutztHp0ah+M5R1VdBbyJIbnSkk+gkCoCW2wpynoY30Wn3JIq65aAIMkQw02sZh6ePKAw32wGv+O0tWYqInwnDAo8Yl4hYKi0Wg312WorD4e5ZCqVY5ARt9EnlpkeFONLTwLWG2NtIsYMJ16pG9Jk9waeKkOCVWU+3mmMp40LSBkxR2SA9F2PTgxgwKmHdXFEztZTrLRcxiLeD/ctofacYqRnBiakuauVSIOR0PGyWxXenKJ+RgCm3Jyk/MU3ZvXh7qdqlhqXs81Jta0EfixYeHxvfxN+ahw297lxxlkOgRQyLQ7RpSOfsUFXS1K6HeiD2++J0adtYggg0GDfPUOU0mR98prXrYu8qVhO1oF/PJ6Yc+6GAb67Lx1ponPYe2WHWAmz0Fc3oxsRffz8qmbBi6RWvl5+FlLn4GAQLJDyB9An5c/4++8uOL7D3j8SK+ajMWKXRllKfVc335SU2vabPWZND7fb2/a2tr40huYID6lApujXdHZ6/vZT/99rW0h7tSY+9MKUvRhIzastqqVkt4mHNQ9eVXnAtDt/nc9zwdaiRl3FQfZnqt+Kg+CrVb/0DdCE+PA==
MtYyc25ygNkg2brF